Intravenous thrombolysis with alteplase is the only approved treatment for acute ischemic stroke, but its efficacy and safety when administered more than 3 hours after the onset of symptoms have ...

Intravenous thrombolysis is a standard treatment of acute ischemic stroke. The efficacy and safety of combining intravenous thrombolysis with argatroban (an anticoagulant agent) or eptifibatide ...

Intravenous thrombolysis in patients hospitalized for cervical artery dissection-related acute ischemic stroke increases the likelihood of home discharge.

A new study published in the Stroke journal revealed a crucial link between early fibrinogen depletion coagulopathy (FDC) and ...

Individuals with STEMI caused by a spontaneous coronary artery dissection (SCAD) who are treated with intravenous thrombolysis prior to coronary angiography fare no worse in the hospital compared with ...

Currently, intravenous thrombolysis is by far the most effective treatment of acute ischemic stroke, and its use can independently strongly increase the proportion of stroke patients surviving.

The European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke provides forty recommendations on the use of thrombolytic drugs. The module working group ...

Citing a low hemorrhage rate and other issues, one expert says the results should be replicated before changing practice.

Stroke patients with dementia treated with intravenous thrombolysis using powerful clot-busting drugs are at no higher risk of brain haemorrhage or death than other patients receiving the same ...

The authors looked at the efficacy and safety of intravenous thrombolysis with alteplase given within three to 4.5 hours after stroke symptom onset. A total of 821 acute stroke patients within ...